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Abstract
Background: Restriction landmark genomic scanning (RLGS) is one of the most successfully
applied methods for the identification of aberrant CpG island hypermethylation in cancer, as well
as the identification of tissue specific methylation of CpG islands. However, a limitation to the utility
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BMC Genomics 2007, 8:446 http://www.biomedcentral.com/1471-2164/8/446of this method has been the ability to assign specific genomic sequences to RLGS spots, a process
commonly referred to as "RLGS spot cloning."
Results: We report the development of a virtual RLGS method (vRLGS) that allows for RLGS spot
identification in any sequenced genome and with any enzyme combination. We report significant
improvements in predicting DNA fragment migration patterns by incorporating sequence
information into the migration models, and demonstrate a median Euclidian distance between
actual and predicted spot migration of 0.18 centimeters for the most complex human RLGS
pattern. We report the confirmed identification of 795 human and 530 mouse RLGS spots for the
most commonly used enzyme combinations. We also developed a method to filter the virtual spots
to reduce the number of extra spots seen on a virtual profile for both the mouse and human
genomes. We demonstrate use of this filter to simplify spot cloning and to assist in the identification
of spots exhibiting tissue-specific methylation.
Conclusion: The new vRLGS system reported here is highly robust for the identification of novel
RLGS spots. The migration models developed are not specific to the genome being studied or the
enzyme combination being used, making this tool broadly applicable. The identification of hundreds
of mouse and human RLGS spot loci confirms the strong bias of RLGS studies to focus on CpG
islands and provides a valuable resource to rapidly study their methylation.
Background
Restriction landmark genomic scanning (RLGS) has been
used to study aberrant CpG island methylation in cancer
for more than ten years. This approach remains one of the
most reliable ways to characterize CpG island hypermeth-
ylation in cancer and has been used both to characterize
differences in aberrant methylation phenotypes and also
to identify tumor suppressor genes. Not only have known
tumor suppressor genes like Cdkn2a (p16), Itga4 (α 4-
integrin) [1], and Igfbp7 [2] been identified as targets of
aberrant methylation in cancer by RLGS, but also novel
tumor suppressor genes such as TCF21 [3], SLC5A8 [4],
ID4 [5], BMP3B [6], and SOCS1 [7] have been identified
by RLGS.
RLGS is a two-dimensional gel electrophoresis method [8]
that allows detection of DNA methylation if a methyla-
tion sensitive landmark enzyme such as NotI is used. Up
to 2,000 end-labeled landmark sites are displayed in a sin-
gle RLGS profile. The labeling of the sites is based on
incorporation of radionucleotides into the NotI half-site
by DNA polymerase. Methylated sites are not digested and
are therefore not labeled, thus they do not contribute to
the two-dimensional pattern of RLGS fragments. Spots
present in a normal profile, but absent from a tumor pro-
file are indicative of methylation of the landmark site. Fur-
thermore, the profiles are quantitative such that spot
intensity directly correlates with the degree of methylation
of a locus, with partial methylation representing the cellu-
lar heterogeneity of the cancer both among the malignant
cells and the associated non-malignant cells. RLGS pro-
files are highly reproducible allowing for comparison of
different tissues (e.g. normal versus tumor tissue) or of
different individuals. Although this approach does not
cover every CpG island in the genome, as microarray-
based approaches may achieve [9,10], RLGS provides
highly reliable data due to the molecular simplicity of the
assay. Unlike microarray-based techniques that depend
upon molecularly complex manipulations such as whole
genome PCR, hybridization, and immunoprecipitation of
methylated DNA, RLGS simply relies upon restriction
digestion of DNA and gel electrophoresis.
Crucial to the successful implementation of RLGS for a
CpG island methylation profiling study is the ability to
identify the sequence of the targets of aberrant methyla-
tion, which has been a bottleneck in the flow of these
types of studies. Significant improvements were made in
RLGS spot cloning ability with the advent of arrayed
boundary libraries, where restriction fragments from the
arrayed library were mapped to the pattern of RLGS spots
[11-13]. Although highly successful, this method is lim-
ited by the tremendous investment in effort required for
each genome of interest and each enzyme combination of
interest.
With the completion of the human and mouse genome
sequences, a bioinformatics approach to RLGS fragment
identification became possible where each restriction frag-
ment's migration in both dimensions could be predicted
to create a virtual RLGS profile. Such an approach could
be applied to any sequenced genome, using any enzyme
combination, and is unaffected by any potential tissue
specific methylation. Furthermore, such an approach
should be far less labor intensive to develop and use than
the arrayed boundary library spot cloning method. The
relative ease of setup and use, plus the incredible flexibil-
ity in the virtual approach, makes such a developmentPage 2 of 18
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identify RLGS spots without the creation of specialized
reagents.
This idea was partially realized in 2001 with a first gener-
ation version of a virtual RLGS gel that was called "Virtual
Genome Scan" and applied to the human genome [14]. In
this system, the restriction fragment migration prediction
formula was based solely on fragment length. Based on
known fragment lengths and spot positions in both
dimensions of rDNA and EBV genome derived spots, a
cubic polynomial was derived giving fragment length as a
function of spot location. By comparing the known posi-
tions of 22 previously identified spots with the positions
of their corresponding fragments on the virtual gel, it was
reported that 75% (16/22) of fragments were in a 12 × 30
pixel window (0.5 cm × 1.5 cm) around the predicted
location, with the remaining fragments in a 24 × 128 pixel
window (1.0 cm × 6.4 cm) [14]. This approach was used
to identify one previously unknown RLGS spot methyl-
ated in neuroblastoma and found to be in the 5' end of the
ALX3 gene [15]. Taking a similar approach, but incorpo-
rating the known chromosome of origin of the RLGS spots
[16] into the predictions, Zardo et al (2002) [17] deter-
mined 96 previously unknown spot identities, and Hong
et al (2003) [18] determined approximately 100 addi-
tional new spot identities.
A second virtual RLGS system (viRLGS) was reported in
2003 and applied to the arabidopsis and mouse genomes
[19]. The migration algorithms used were similarly based
solely on the length of the DNA fragments. In the mouse
virtual profile it was observed that there were 710 more
spots on the virtual profile than are found on the same
region of the actual profile. Given that in the mouse
genome, unlike the human genome, many of the land-
mark sites (NotI sites) are within repetitive elements like
LTRs, Repeat Masker was able to remove nearly 500 of
these extra spots from the virtual profile [19]. This
approach was used to identify tissue specifically methyl-
ated RLGS spots in mouse [20] and to identify CpG
islands that become hypomethylated in mouse ES cells
when DNA methyltransferases are knocked out [21].
With approximately 2500 spots on a 35 × 43 cm gel in the
human NotI-EcoRV-HinfI enzyme combination most
commonly used, the average distance between neighbor-
ing spots is 0.7 cm. To generate a virtual image that
approximates the true image, such that the relative pre-
dicted positions of any two neighboring spots does not
flip-flop, the window of error for spot prediction should
be, at most, half this average distance or 0.35 cm. One
confounding issue is that others have demonstrated a con-
siderable correlation between DNA fragment curvature
and gel mobility [22-25]. Thus, it is clear that, while a sim-
ple fragment migration model based upon fragment
length alone is a good start, it must be improved upon. In
addition, since in the human genome NotI sites rarely cut
in repetitive elements, use of a repeat masker does not
help to remove the extra spots in a human virtual RLGS
profile.
We have developed a novel system of virtual RLGS
(vRLGS) using first and second dimension migration
algorithms that use the sequence characteristics of each
fragment along with the fragment length to determine
spot position. These algorithms were determined based
on the identification of 795 RLGS spots in the human
NotI-EcoRV-HinfI profile. In addition, we have defined a
filter to remove extra spots from both the human and
mouse vRLGS profiles based on GC content. We report
greatly improved accuracy of pattern prediction even
when the migration algorithms are applied to different
enzyme combinations and different genomes from which
they were derived. These improvements are combined
with a novel graphic interface that allows for visualization
of virtual spots that 1) look like real spots, and 2) allow
the user to overlap the virtual and real profiles. These
changes make the bioinformatics approach to identifying
RLGS spots of interest a highly viable and effective alter-
native to more complex RLGS spot cloning methods.
Results and discussion
Spot location prediction
vRLGS profiles for the human NotI-EcoRV-HinfI, AscI-
EcoRV-HinfI, and the mouse NotI-EcoRV-HinfI genome
and enzyme combinations were generated as described in
the Materials and Methods. These virtual profiles were
then compared to the laboratory gels that serve as our
"Master Profiles" for each. Fig 1A contains a sample screen
shot of Conime. The upper panel shows the overlap of the
two gels and is colorized with the laboratory gel contrib-
uting blue and the virtual gel contributing red, while areas
of overlap appear dark purple. The strongest spots on the
laboratory gel arise from the high copy number rDNA
sequences. Some of these spots line up quite well with the
virtual spots, but others do not due to polymorphism in
subsets of these highly repeated units. The virtual profile
does not have polymorphic information for these subsets
of the repeats, explaining why some of the darkest spots
do not align. The image in Fig 1A is zoomed out to show
the entire gel, while in Fig 1B the image is focused on a
specific region of interest. This region of the gel is a por-
tion of section 2D from the master PBL profile previously
described [26]. Spots 38, 45, 46 and 48 have been identi-
fied and confirmed, and their positions on both the actual
RLGS gel (left) and the virtual gel (right) are shown. The
overlay in the top panel shows how closely the migration
algorithms correctly predict the positions of the spots in
both dimensions.Page 3 of 18
(page number not for citation purposes)
BMC Genomics 2007, 8:446 http://www.biomedcentral.com/1471-2164/8/446
Page 4 of 18
(page number not for citation purposes)
vRLGS in the Conime interfaceFigure 1
vRLGS in the Conime interface. Using the March 2006 freeze of the human genome we generated a vRLGS profile for the 
enzyme combination NotI-EcoRV-HinfI and loaded it into the Conime user interface along with the human master profile. A) 
Three veiwports in the Conime interface. The master profile is seen in the bottom left and the virtual profile is shown on the 
bottom right. The upper panel is a composite image of the two with the virtual profile contributing red and the master profile 
contributing blue. Areas of spot overlap between the two profiles appear as dark blue. B) Zoomed in view of the gels in A). 
Spots 38, 45, 46, and 48 are known sequences and are labeled on both the master profile and virtual profile with their overlap 
shown in the upper panel. The arrow in all three profiles indicates the spot of interest on the master profile, the top candidate 
sequence on the virtual profile, and their overlap. To the right is shown a window that can be selected to provide information 
about the virtual spot of interest (clicking on the spot with the arrow). This spot of interest is found at chr16:86976875.
BMC Genomics 2007, 8:446 http://www.biomedcentral.com/1471-2164/8/446In order to identify a top candidate sequence for the spot
adjacent to 46 with the arrow, the virtual profile is clicka-
ble. This clickable window presents information about
the restriction fragment mapping to that position in the
vRLGS profile, as shown in Fig 1B. Each vRLGS spot has a
unique identifier, giving the chromosome followed by the
base position on that chromosome. The unique identifier
for each virtual spot is the position of either the NotI site
or the HinfI site in the 2nd dimension fragment, depend-
ing on the orientation of the sequence in the database
with the 3' end of the restriction fragment used. Therefore,
even though a single NotI site can potentially generate
two spots, each will get a unique identifier with the spot
generated by the fragment 5' to the NotI site named by the
position of the NotI site, and the spot generated by the
fragment 3' to the NotI site named by the position of the
HinfI site. Additional information concerning the CpG
characteristics of the region around the NotI site are also
included and discussed in more detail below.
Using sets of confirmed cloned spots for each gel, we com-
puted the distance between the predicted X and Y position
and each spots' actual X and Y positions on the master
profiles. We also computed the Euclidean distance
between the spots' predicted and actual location on the
gel. These distances represent the spot prediction error
and give an objective measure of the accuracy of the DNA
fragment migration algorithms in each dimension. Table
1 presents the results of the prediction formulas applied to
the three gels. We give the median error, the mean error,
and the root mean squared error for the X and Y dimen-
sions as well as the Euclidean prediction errors, the 90'th
percentile error, (the max error after dropping 10'th per-
centile of spots with the worst error,) and the root mean
square error of the 90'th percentile of spots with the least
error. The large improvement in the RMS of the 90th per-
centile spots compared to the entire data set indicates that
a relatively few number of outliers are strongly influenc-
ing the mean error. Importantly, the maximum difference
between actual spot position and virtual spot position for
the 75th percentile of spots is 0.12 cm in the 1st dimension
and 0.24 cm in the 2nd dimension. This represents a signif-
icant improvement over the maximum error for the 75th
percentile of spots of 0.5 cm and 1.5 cm previously
reported for a virtual RLGS approach [14].
Factors other than length also contribute to migration
Spot locations in laboratory RLGS gels depend not only
upon DNA sequence properties, but also upon laboratory
conditions. Temperature, ionic strength of buffers, gel
running times, and the physical handling of RLGS gels all
affect the migration of DNA fragments. Exact spot loca-
Table 1: Measure of migration prediction accuracy for all profiles
Human NotI-EcoRV-HinfI (n = 795) Human AscI-EcoRV-HinfI (n = 133) Mouse NotI-EcoRV-HinfI (n = 530)
Func Median Mean RMSc 90%d 90%-RMS Median Mean RMS 90% 90%-RMS Median Mean RMS 90% 90%-RMS
(1)a X 0.17b 0.22 0.28 0.45 0.20 0.14 0.25 0.44 0.52 0.19 0.35 0.49 0.99 0.79 0.35
(2) X 0.14 0.17 0.23 0.34 0.16 0.13 0.23 0.55 0.34 0.14 0.15 0.23 0.76 0.36 0.17
(3) X 0.13 0.15 0.20 0.31 0.14 0.12 0.13 0.17 0.26 0.13 0.11 0.18 0.74 0.29 0.12
(4) X 0.10 0.14 0.20 0.30 0.12 0.09 0.19 0.53 0.27 0.11 0.13 0.22 0.77 0.34 0.15
(5) X 0.09 0.11 0.16 0.24 0.10 0.07 0.10 0.13 0.20 0.09 0.09 0.16 0.75 0.23 0.10
(6) X 0.08 0.11 0.15 0.22 0.10 0.06 0.09 0.12 0.18 0.08 0.09 0.16 0.75 0.22 0.10
(7) X 0.06 0.09 0.14 0.18 0.08 0.07 0.08 0.11 0.18 0.08 0.05 0.12 0.74 0.15 0.06
(8) Y 0.26 0.48 0.85 1.08 0.36 0.26 0.37 0.53 0.82 0.32 0.28 0.49 0.94 1.04 0.37
(9) Y 0.25 0.40 1.77 0.71 0.30 0.23 0.37 0.81 0.61 0.26 0.29 0.47 1.11 0.80 0.34
(10) Y 0.21 0.45 4.44 0.55 0.24 0.19 0.30 0.44 0.64 0.25 0.25 0.38 0.83 0.65 0.28
(11) Y 0.19 0.34 1.67 0.62 0.24 0.17 0.30 0.70 0.44 0.21 0.24 0.41 1.07 0.64 0.27
(12) Y 0.16 0.27 1.42 0.43 0.18 0.17 0.23 0.33 0.40 0.19 0.17 0.30 0.77 0.52 0.21
(13) Y 0.15 0.26 1.42 0.43 0.18 0.18 0.21 0.29 0.40 0.18 0.17 0.29 0.76 0.50 0.20
(14) Y 0.14 0.25 1.43 0.39 0.17 0.12 0.18 0.28 0.37 0.15 0.15 0.28 0.75 0.50 0.19
(1/8) Eucl.e 0.38 0.58 0.90 1.13 0.44 0.37 0.51 0.69 1.14 0.43 0.52 0.79 1.37 1.64 0.62
(2/9) Eucl. 0.32 0.48 1.78 0.76 0.36 0.30 0.51 0.97 0.90 0.34 0.37 0.57 1.34 0.89 0.40
(3/10) Eucl. 0.29 0.52 4.45 0.64 0.30 0.25 0.36 0.47 0.67 0.30 0.30 0.46 1.12 0.69 0.32
(4/11) Eucl. 0.26 0.40 1.68 0.67 0.29 0.24 0.42 0.88 0.56 0.27 0.30 0.51 1.32 0.80 0.33
(5/12) Eucl. 0.22 0.32 1.43 0.48 0.23 0.21 0.27 0.36 0.44 0.23 0.22 0.37 1.07 0.57 0.24
(6/13) Eucl. 0.21 0.31 1.43 0.46 0.22 0.20 0.25 0.31 0.42 0.21 0.21 0.36 1.07 0.53 0.24
(7/14) Eucl. 0.18 0.28 1.43 0.44 0.20 0.16 0.22 0.30 0.38 0.18 0.18 0.34 1.05 0.53 0.21
aSee Materials and Methods for descriptions of functions according to the number; bAll values in cm; cRoot Mean Square; d Maximum error of the 90th percentile of 
spots (dropping the 10th percentile of spots with the worst error). e Euclidean distance.Page 5 of 18
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duced from the same DNA specimen, although their
relative positions do not change. Thus, our prediction for-
mulas must model not only migration distance based on
sequence properties, but also the effects of warping and
distortion in the gel used to create the Master Profile.
Comparing the three formulas (see Materials and Meth-
ods) based on fragment length (1, 2, 3, and 8, 9, 10) there
is marked improvement from the logL formula to the
cubic to the quintic polynomial. Adding a linear curvature
term to the cubic and quintic length polynomials
improves both formulas (4, 5, 11, and 12), with the quin-
tic polynomial retaining an advantage. Replacing curva-
ture by the GC ratio (ratio of G or C base pairs to total
fragment length) gives a slight, but non-significant,
improvement (6 and 13). Fragment GC ratio is highly cor-
related with curvature, suggesting that these terms are
interchangeable. Computing GC ratio is much simpler
than computing curvature and is far preferable.
Each spot location is based on two fragments, one that
migrates in the X-direction and a second that migrates in
the Y-direction. The X-direction formulas discussed above
depend upon the sequence of the first fragment in the
pair. The last X-direction formula (7) adds a linear term
proportional to the log of the length of the second
sequence. This can be viewed as slightly adjusting the X-
coordinate based on the Y-coordinate of the spot. Simi-
larly, the Y-direction formulas depend upon the sequence
of the second fragment in the pair. The last Y-direction for-
mula (14) adds a linear term proportional to the log of the
length of the first sequence. The last formula gives the best
fit on all three gels.
The improvement in prediction formula using the quintic
polynomial with GC ratio and the Log of the other dimen-
sion fragment length can be easily seen by visually com-
paring computer generated vRLGS gels with laboratory
gels. Figure 2, shows a region in section 2D of the master
human NotI-EcoRV-HinfI profile and the corresponding
regions in virtual profiles generated by various formulas.
Spots labeled 1 through 7 are previously cloned RLGS
spots allowing the correct identification of each of the cor-
responding virtual spots, as shown in Fig 2. The swirl
shape seen in the master profile is much more evident in
Fig 2C and 2D. Of particular importance are the relative
positions of spots 3, 5, and 6. In Fig 2A and 2B, the posi-
tion of spot 5 is below spots 3 and 6 in the virtual profiles,
but in the master profile spot 5 is above spots 3 and 6. This
is remedied in Fig 2C and 2D where adding in a sequence
specific factor (GC ratio) corrects for the slower migration
of spot 5. Finally in Fig 2D, although the absolute posi-
tions of spots 3, 4, 5, and 6 are not perfect in the virtual
gel, their relative spacing is correct within a distance equal
to the height of the spots.
More broadly, Table 1 shows that by using the migration
formulas shown in Fig 2D, the median error between pre-
dicted position and actual position for all cloned spots is
0.06 cm in the 1st dimension and 0.14 cm in the 2nd. To
address whether these data were due merely to over-fitting
of the migration formulas to the spot migration data, we
randomly selected half of the cloned spots to be used to
derive the migration formulas and measured the accuracy
of the other half. We found a median error in the 1st
dimension of 0.06 cm and of 0.16 in the second dimen-
sion (data not shown), demonstrating that the data
shown in Table 1 is not due to over-fitting of the data.
Such improvement over previous virtual RLGS
approaches dramatically improves the utility of virtual
RLGS for spot identification since the error is less than
half the average distance between spots. This makes it
much more likely that the pattern of spots relative to each
other will be faithfully preserved in the virtual image even
if some small error remains in their absolute positions.
There are two confounding factors in modeling DNA frag-
ment migration in these gels that make using a simple
migration model based on the log of the fragment size
insufficient. These are the physical imperfection of these
gels as described above and the sequence dependent
geometry of the DNA fragments. We hypothesize that the
improvement from the logarithmic to cubic to quintic for-
mulas probably reflects the better ability of the quintic
polynomial to model physical gel distortion. The variabil-
ity in physical gel distortion from one Master Profile to
the other can be accounted for by independent derivation
of the coefficients based upon known spots.
The improvements seen by adding in the GC ratio factor
reflect the sequence dependent influence of DNA frag-
ment geometry on fragment migration. Although this is
an indirect measure of geometry, it performed similarly to
the use of the geometry prediction program Curva. We
believe that this factor is the most difficult to model prop-
erly and is the major reason some error remains in these
models.
The improvement in the final formula, adding in the log
of the length of the other dimension fragment, reflects the
better ability of this formula to model physical gel distor-
tion and possibly the influence of DNA fragment geome-
try. The fact that vertical migration in the Y-direction
depends somewhat on the size of the horizontal fragment
is not so surprising since vertical migration follows hori-
zontal migration. More remarkable is that the X-location
seems to depend upon the size of the vertical fragment,
even though horizontal migration precedes vertical migra-Page 6 of 18
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First and second dimension migration formulasigure 2
First and second dimension migration formulas. Master and vRLGS images for the human genome with the enzyme 
combination NotI-EcoRV-HinfI zoomed in on region 2D of the master profile. Spots labeled 1–7 are known sequences and are 
labeled on both the master and virtual profiles, with their overlap shown in the upper panels. The virtual spot labels are grey 
and outlined in red. A) – D) show the same window of the gels using the indicated migration formulas for the first and second 
dimensions (see materials and methods for formulas).
BMC Genomics 2007, 8:446 http://www.biomedcentral.com/1471-2164/8/446tion. We hypothesize that vertical fragments do not neces-
sarily migrate in a perfect vertical line through a gel, but
actually move slightly along the X-direction, explaining
why the X-location would depend upon the vertical frag-
ment size.
Filtering extra spots from the vRLGS
RLGS is typically applied using a methylation sensitive
landmark enzyme such as NotI or AscI, with the goal of
identifying methylation differences at CpG islands
between state A and state B (i.e.; normal vs. tumor, or tis-
sue A vs. tissue B). Upon close examination of the vRLGS
profile it became clear that there were significantly more
virtual spots than real spots. This can be explained by the
fact that certain NotI sites are methylated, even in normal
tissues, and this may be tissue specific. The presence of
these extra spots on the virtual profile makes the pattern
correlations with the actual RLGS profile much more dif-
ficult to discern. We investigated whether a difference in
the sequence surrounding the NotI sites could be found
between real RLGS spots and extra spots seen only on the
virtual profile. We identified 120 extra spots from the vir-
tual profile in regions of the gel where most of the actual
RLGS spots had already been identified. We compared the
sequence of the NotI site +/- 200 bp (total of 400 bp) from
the 120 extra virtual spots to 600 cloned and confirmed
actual RLGS spots. Figure 3 shows the distributions of
GC%, observed over expected CpG ratio, and CpG count
in the 120 extra virtual spots and the 600 actual RLGS
spots. We tested various combinations of these three fac-
Sequence characteristics surrounding the NotI site of extra spots and real spotsFig re 3
Sequence characteristics surrounding the NotI site of extra spots and real spots. Analysis of 200 bp + and – the 
NotI site for 120 extra spots and 600 real spots from the human NotI-EcoRV-HinfI RLGS profile was performed. In all four 
charts, data for the extra spots is shown in pink and data for real spots is shown in blue. The Y axes for all are the percentage 
of the class of spots showing the measure indicated on the X axis A) Measures of GC content. B) Observed/expected CpG 
ratio. C) Number of CpGs. D) The percentage of spots retain after eliminating all spots that fail to meet the three indicated 
criteria. The boxed data points show the percentage of real and extra spots retained when all spots that fail to meet all three 
of the following criteria are eliminate: 50%
96% retained
46% eliminated
A)
D)C)
B)Page 8 of 18
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order to maximize the number of extra spots identified,
yet minimize the number of actual spots identified. We
found that if we filtered out NotI sites whose surrounding
400 bp of sequence had less than 50% GC, a CpG ratio of
less than 0.55, and a CpG count of less than 20, we could
eliminate 46% of our 120 extra virtual spots, yet retain
96% of our 600 actual spots.
The results of this filtering can be seen in figure 4A and 4B.
In each, the lower left is the master RLGS profile zoomed
in to section 3D, with the corresponding region of the vir-
tual gel shown in the right panel. The numbered spots are
all identified and confirmed and are therefore noted on
the virtual profile. Spot A (Fig 4A) represents a spot for
which identification of a good candidate sequence is
extremely difficult because of extra spots (indicated with
red Xs) seen on the virtual profile complicating the virtual
pattern near spot A. However, when we applied the filter
described above to remove all extra spots based on the
sequence environment of the NotI site, the best candidate
sequence for spot A became immediately obvious (Fig
4B).
We note that the filtering criteria identified are similar to
criteria used to define CpG islands. We find that NotI sites
in regions that look less like CpG islands are more likely
to be extra spots. This is consistent with the idea that CpG
islands are protected from methylation in normal cells in
most cases but CpG dinucleotides outside CpG islands are
highly methylated, and also explains why even though
only 89% of NotI sites in the human genome reside in
CpG islands, 96% of identified RLGS spots are in CpG
islands (Table 2). Interestingly, as described below and
shown in Figure 5, it is often true that RLGS loci found to
exhibit tissue specific methylation arise from NotI sites
that we would filter out (Fig 5B), and are therefore less
"CpG island-like." It was recently found that there are
many regions of hypomethylation in mouse testis DNA
compared to DNA in somatic tissues and that these chro-
mosomal regions are defined by lower GC content [27].
These observations suggest that there may be a relation-
ship between the potential of a locus to exhibit tissue spe-
cific methylation and the "CpG island-like" characteristics
of the sequence.
Efficacy of vRLGS for novel spot identification
Using the human NotI-EcoRV-HinfI vRLGS profile pro-
duced with the migration algorithms derived from 300
spots cloned from the library mixing gel approach and
incorporating DNA curvature and GC ratio, we attempted
to identify 337 unknown RLGS spots. We identified a top
candidate sequence for each spot and designed PCR prim-
ers that fall within the 2nd dimension fragment. For 20
spots, we chose 2 candidate sequences to test because one
candidate appeared only slightly better than the other. We
then used the primers for the candidate sequence to
amplify DNA eluted from the spot in question, as well as
a nearby spot. Accurate prediction of a spot sequence was
determined if a strong PCR product was obtained when
that spot was used as template, but no product or a very
weak product was detected using a nearby spot as tem-
plate.
Figure 4 shows an example of the vRLGS spot sequence
verification experiment. We predicted the sequence of
spots 36, 56, (not shown in this window) 62, and 68 from
section 3D of the master profile based on the virtual spots
indicated (Fig 4B). In all four cases, the PCR experiment
described above showed a strong band when the primers
from the predicted sequence were used with template
DNA from the spot of interest, but no band when DNA
from a nearby spot was used as template. This PCR confir-
mation experiment was successfully implemented for 293
of the candidate sequences and 246 were found to be cor-
rect by this method while 47 candidates were found to be
incorrect. For the remaining 44 spots, the PCR experiment
was inconclusive either due to a failed PCR reaction even
in total genomic DNA, or because a positive band was
found in both the expected spot DNA as well as the nega-
tive control spot DNA. For these, we tested the accuracy of
the candidates either with BAC mixing gels or with mixing
gels of the NotI-EcoRV fragments PCR cloned from
genomic DNA (materials and methods). 30 of the 44
tested by this method were correct. For the 20 spots where
we tested 2 candidate sequences, we found a clear result of
only one of the two sequences correct in each case. Over-
all, 276 of the 337 RLGS spots we attempted to clone by
the vRLGS approach were confirmed to be correct.
Application of vRLGS to other genomes and enzyme 
combinations
We have demonstrated excellent utility and pattern corre-
lation of the vRLGS profile with the human NotI-EcoRV-
HinfI enzyme combination from which the migration
algorithms and extra spot filtering were derived. To
address whether these improvements to vRLGS were
based on sound principles or were simply due to over fit-
ting of the data, we applied the same migration factors to
create a human AscI-EcoRV-HinfI vRLGS profile (Addi-
tional file 1). In addition we created vRLGS profiles for the
mouse genome using the NotI-EcoRV-HinfI (Additional
file 2). We used cloned spots as anchor points for each
and calculated the formula coefficients as described in the
materials and methods. Table 1 shows the error of the pre-
diction formulas for the cloned spots in the two human
profiles and the NotI-EcoRV-HinfI mouse profile with
795, 133, and 530 spots cloned, respectively. These data
demonstrate that the migration algorithms developed for
the human NotI-EcoRV-HinfI profile incorporating frag-Page 9 of 18
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vRLGS spot candidate identification and confirmationFigure 4
vRLGS spot candidate identification and confirmation. Human NotI-EcoRV-HinfI profiles zoomed into section 3D. 
Identified spots are labeled on the lower panels for A) and B), with the upper panels showing the overlap of the actual and vir-
tual spots of interest – 62 and 68 – circled. All other labeled spots were previously identified. A) The vRLGS image with the 
extra spot filtering off. Extra spots are indicated with red Xs. Spot A is a spot of interest for which the presence of extra spots 
makes the selection of the best candidate sequence difficult. B) The same vRLGS image with the extra spot filtering on. Faded 
red Xs indicate the positions the extra spot occupied in A), but are not seen with the filtering on. The candidate sequence for 
spot of interest A becomes immediately obvious. C) Example of PCR candidate sequence confirmation. DNA was eluted from 
the spots indicate as template DNA for PCR using primers derived from the candidate sequence for the spots of interest. In 
the last two lanes, primers for the candidate sequence for spot 68 were used to amplify DNA eluted from spot 62 and spot 68. 
Only the when the DNA eluted from spot 68 was used as template was a band observed. This is confirmation that the 
sequence predicted by the vRLGS in A) and B) is correct for spot 68. The same is true for spots 36 and 56 (not shown in A) 
and B)), and 62.
BMC Genomics 2007, 8:446 http://www.biomedcentral.com/1471-2164/8/446ment length as well as information about the GC content
of each fragment are based on sound principles and can
be broadly applied to different enzyme combinations and
genomes.
As a further test of the utility of the vRLGS system in the
mouse genome, we used vRLGS to identify the sequence
of 126 spots from the mouse NotI-EcoRV-HinfI master
profile. In addition, turning on or off the filtering out of
extra spots can allow for use of vRLGS to identify tissue
specific methylation spots. Figure 5 shows section 2F from
the mouse NotI-EcoRV-HinfI profile with spots 63, 64,
and 79 previously identified and the indicated spot not
present in the master profile or in a mouse liver profile.
This spot was, however, found on a mouse intestine pro-
file (Fig 5A first panel). When using the vRLGS profile
Application of vRLGS to the mouse NotI-EcoRV-HinfI profile to identify a tissue specific methylation locus and confirmation by BAC lone mixing gelFigure 5
Application of vRLGS to the mouse NotI-EcoRV-HinfI profile to identify a tissue specific methylation locus and 
confirmation by BAC clone mixing gel. Mouse RLGS profiles zoomed in on section 2F. A) Actual mouse RLGS profiles 
from intestine and liver. The circled spot is present in the intestine profile but absent from the liver profile. B) vRLGS images 
of the same region with the extra spot filtering turned on in the first panel, but turned off in the second panel. The third panel 
shows the overlay of the mouse master profile where the spot of interest is not seen and the vRLGS profile with the extra 
spot filtering turned off. The intestine specific spot of interest is only seen on the vRLGS profile in the extra spot filtering is 
turned off. This candidate sequence from the vRLGS profile was confirmed to be correct by performing a BAC clone mixing 
gels shown in the third panel of A) where the spot of interest is greatly enhanced by the radio-labeled BAC.
Table 2: Summary of RLGS spot characteristics
Human NotI-EcoRV-HinfI (n = 795) Mouse NotI-EcoRV-HinfI (n = 530)
CpG island 760 96% 459 87%
Gene Homology 745 94% 503 95%
Intergenic 49 6% 27 5%
5' end 569 76% 439 87%
Non-5' end 176 24% 64 13%Page 11 of 18
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spot of interest was not present on the virtual profile (Fig
5B first panel), however, when we did not filter out the
extra spots, the virtual spot was present (Fig 5B second
panel). The third panel of Fig 5B shows the composite
image of the vRLGS profile with the extra spots retained
aligned with the master profile and the candidate virtual
spot for the intestine specific spot of interest indicated. We
confirmed the correct identification of this intestine spe-
cific spot by BAC clone mixing gel (Fig 5A third panel).
These data demonstrate that although in most cases filter-
ing out the extra spots helps with the cloning of a particu-
lar spot of interest by reducing the complexity of the
virtual pattern (Fig 4), for some specific spots in special
situations (i.e. – tissue specific methylation, hypomethyl-
ation in cancer genomes) it is necessary to keep the extra
spots in order to identify the spot of interest.
Virtual spot identification of genetically mapped loci
As a further test of the general applicability of our vRLGS
system, we applied it to the mouse genome for two
enzyme combinations where significant genetic mapping
of RLGS spots had been previously published. Impor-
tantly, these were completely naïve data sets to test the
vRLGS application since we had no previously cloned
spots to use to derive coefficients for the DNA fragment
migration formulas. We used the exact same formulas that
were used for the mouse NotI-EcoRV-HinfI vRLGS pro-
files, again demonstrating that the accuracy of this system
is due to the migration formulas being based on sound
principles.
A set of 195 RLGS spots from the enzyme combination
NotI-PstI-PvuII that vary between C57BL/6J and DBA/2J
have been previously mapped using recombinant inbred
strains (BXD) [28]. For the NotI-PvuII-PstI enzyme com-
bination, a set of 575 RLGS loci were mapped in a C57BL/
6 × M. Spretus interspecific backcross (BSS) [29]. We
aligned the vRLGS profiles for both enzyme combinations
with actual gels as shown in Figure 6. Excellent pattern
matching was observed and we attempted to identify a
total of 263 mapped C57BL/6 spots on the vRLGS pro-
files. We identified obvious candidate virtual spots for 60/
96 spots mapped in the BXD data (Fig 6A) and 140/167
spots mapped with the BSS data (Fig 6B) for a total of 200
C57BL/6 spot candidate virtual sequences. We then
looked at the position of the NotI site in the mouse
genome for each of the candidate sequences and com-
pared that with the genetic mapping data available for 184
of these RLGS spots (mapping data was not found for 16
spots). We found that 92% of the virtual RLGS spot candi-
date sequences were consistent with the genetic mapping
BXD data and 98% were consistent with the genetic map-
ping BSS data (Additional files 3 and 4, respectively).
These data provide an independent proof of the accuracy
and utility of our vRLGS system and demonstrate that this
is not merely due to over fitting of the migration algo-
rithms.
RLGS spot sequence characteristics
Through a combination of methods including boundary
library mixing gels, BAC clone mixing gels, and vRLGS we
have identified and confirmed the sequence of 795
human NotI-EcoRV-HinfI spots (Additional file 5) and
530 mouse NotI-EcoRV-HinfI spots (Additional file 6). To
study the sequence characteristics and genomic context of
each of these RLGS spots, we looked at the NotI site plus
or minus 200 bp and asked if this 400 bp sequence fell
within a CpG island and if the CpG island was within 5 kb
of the transcriptional start site of a known gene or mRNA
sequence (Table 2). We found that 96% of the human
RLGS spots and 87% of the mouse RLGS spots were
located in CpG islands. Greater than 90% of these were
associated with genes in both genomes and were found at
the 5' ends of genes for 76% in the human genome and
87% in the mouse genome. These data confirm the find-
ings of multiple smaller data sets demonstrating the
strong bias of RLGS data to focus on CpG islands in the
regulatory regions of genes where the best understood
biological consequences of aberrant hypermethylation
arise.
Conclusion
We have presented a novel bioinformatics tool to rapidly
identify RLGS spot sequences by creating a virtual RLGS
profile to connect the position of spots with genomic
sequences. This system of vRLGS builds upon previous
systems by incorporating migration algorithms for both
dimension that include consideration of the sequence
characteristics of every restriction fragment, as well as the
size. In addition, this vRLGS system predicts which virtual
spots will not be present on most normal profiles and can
filter these extra spots out, or leave them in the profile if
the research being done dictates a need to identify such
loci.
The accuracy and utility of this vRLGS system was demon-
strated on both the human and mouse genomes and for
multiple enzyme combinations, demonstrating the broad
applicability of the principals behind the migration algo-
rithms. Although this system is still not able to perfectly
mimic an actual gel, the data demonstrate an excellent
ability to easily identify the most likely candidate
sequence for a spot of interest in most cases. As more
RLGS spot clone information becomes confirmed, the
new data can be incorporated into the migration algo-
rithms to improve the overall fitting of the virtual profile
to the actual profile.Page 12 of 18
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Application of vRLGS to the mouse genome with alternative enzyme combinationsFigure 6
Application of vRLGS to the mouse genome with alternative enzyme combinations. A) A mouse vRLGS profile 
was generated for the enzyme combination NotI-PstI-PvuII (lower right) and compared with an actual gel (lower left). Spots of 
interest, previously mapped in BXD recombinant inbred strains are labeled on the actual gel and candidate vRLGS spots are 
labeled that are located in the same genomic region as the genetically mapped spots. The circles in the upper panel indicate the 
overlap between the actual and virtual spots of interest. B) Same as in A) except using the enzyme combination NotI-PvuII-
PstI. The spots of interest are genetically mapped in a BSS interspecific backcross.
BMC Genomics 2007, 8:446 http://www.biomedcentral.com/1471-2164/8/446The reporting of the confirmed identification of 795
human RLGS spots and 530 mouse RLGS spots provides a
valuable tool for researchers using RLGS on human sam-
ples or in mouse models. The characteristics of these iden-
tified RLGS spots confirm the value of the RLGS approach
to focus aberrant methylation studies on CpG islands. The
vRLGS tool can now be used to identify the top candidate
sequences for RLGS spots whose pattern of methylation in
cancers is of interest. Confirmation of the accuracy of the
prediction allows for rapid identification of novel targets
of CpG island hypermethylation.
Methods
The software we used for vRLGS software is divided into
four components: enzyme simulation, methylation pre-
diction, location prediction and vRLGS image generation.
We also used a software tool called Conime for visualizing
vRLGs images and comparing them with laboratory RLGS
gels. Dr. Stanislav Volik UCSF wrote the enzyme simula-
tion software, rlgs.pl, although we made extensive modi-
fications. Dr. Ping Liang at Roswell Park Cancer Institute
developed the methylation prediction module. All other
software, including Conime, was developed at The Ohio
State University (OSU). Perl scripts are available on the
web [30].
Enzyme simulation (rlgs.pl)
In laboratory RLGS, three enzymes digest genomic DNA
into fragments for gel electrophoresis. The program
rlgs.pl, written in the programming language Perl, simu-
lates this process using pattern matching on DNA
sequences from genome databases. Input to rlgs.pl is a
fasta file containing a chromosome DNA sequence and
three strings representing the recognition sites of the three
enzymes. The chromosome sequence and the recognition
sites are represented as strings of the characters A, C, G, T.
rlgs.pl splits the chromosome sequence at substrings
which match the first recognition site, creating a set Frag1
of subsequences. The program then splits each subse-
quence at substrings which match the second recognition
site creating set Frag2. Finally, it splits each resulting sub-
sequence at substrings which match the third recognition
site creating set Frag3.
Each fragment has two cleavage sites, one at each end-
point. (The two exceptions are the fragments correspond-
ing from the very first and the very last subsequences of
the chromosome.) A spot which appears on a laboratory
RLGS gel is created by a radioactive nucleotide bound to a
first enzyme cleavage site. Thus, rlgs.pl discards any subse-
quences which do not contain a first enzyme cleavage site.
RLGS fragments are separated along the first dimension
after the application of the second enzyme. The third
enzyme is applied after this first dimension separation
and the resulting fragments are then separated in the sec-
ond dimension. Thus two fragments determine the loca-
tion of each spot on the gel, one from before and one
from after application of the third enzyme. rlgs.pl pro-
duces pairs of subsequences corresponding to these two
fragments for each spot. The first element of each pair is
from set Frag2 while the second is from set Frag3. The sec-
ond element is a subsequence of the first. The pairs of sub-
sequences are used to determine the spots appearing on
the vRLGS image as described below.
If a fragment is too long or too short, then it will fail to
migrate or will migrate all the way across the gel. Such
fragments do not create spots on the gel. We eliminated
any fragment pairs whose first fragment contained less
than 400 or more than 8000 base pairs or whose second
fragment contained less than 100 or more than 3000 base
pairs.
Methylation prediction
Methylation sensitive enzymes cut DNA only at unmeth-
ylated binding sites. However, genome databases do not
indicate whether a binding site is methylated or unmeth-
ylated. Thus, rlgs.pl treats all binding sites as unmethyl-
ated, creating many fragment pairs which do not
correspond to laboratory RLGS spots. Eliminating such
spots from the vRLGS image improves the quality and
accuracy of our vRLGS image. We identified 120 extra
spots from the virtual profile in regions of the gel where
most of the actual RLGS spots had already been identified.
We compared the sequence of +/-200 base pairs around
each spot's NotI site with the sequence around the NotI
sites of the 600 cloned and confirmed actual RGLS spots
and predict the methylation status of the NotI sites as
described in the Results and Discussion.
Location prediction
The most critical component in virtual RLGS is the ability
to accurately predict the location of each spot on the gel.
This location is determined by two fragments, one from
before and one from after the application of the third
enzyme. rlgs7.pl produces pairs of subsequences corre-
sponding to RLGS fragment pairs.
fff2cnm.pl is a Perl program which converts pairs of DNA
sequences into spot locations on a virtual RLGS image. We
experimented with a number of different prediction for-
mulas and report on seven of them here. These formulas
depended on three parameters: DNA sequence length,
curvature and GC ratio. The DNA sequence length is sim-
ply the number of base pairs in the sequence. The curva-
ture is the curvature of the DNA fragment. We used the
CURVA [31] software to calculate a sequence-dependent
spatial trajectory of the DNA molecule and respective cur-
vature distribution therein for each virtual RLGS restric-Page 14 of 18
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BMC Genomics 2007, 8:446 http://www.biomedcentral.com/1471-2164/8/446tion fragment. The curvature in the position "n" is defined
as normalized reciprocal radius of the arc approximating
the arc-size DNA fragment centered in the position "n".
The GC ratio is the percentage of G's and C's in the DNA
sequence.
RLGS images are usually oriented so that DNA fragments
migrate from right to left along the x-axis and then from
top to bottom along the y-axis. Thus the formulas predict
each spot's distance from the upper-right hand corner of
the gel.
The formulas for predicting the horizontal distance from
the right edge of the gel are:
1. Log: a1 + a2 log(L1 + a3)
2. Cubic polynomial: a0 + a1 L1 + a2  + a3 
3. Quintic polynomial: a0 + a1 L1 + a2  + a3  + a4 
+ a5 
4. Cubic & curvature: a0 + a1 L1 + a2  + a3  + b C1
5. Quintic & curvature: a0 + a1 L1 + a2  + a3  + a4  +
a5  + b C1
6. Quintic & GC ratio: a0 + a1 L1 + a2  + a3  + a4  +
a5  + b GC1
7. Quintic & L2 & GC ratio: a0 + a1 L1 + a2  + a3  + a4
 + a5  + b0 Log(L2) + b1 GC1
where L1, C1 and GC1 are the length, curvature and GC
ratio of the first sequence in the pair and L2 is the length
of the second sequence.
The formulas for predicting the vertical distance from the
top edge of the gel are similar to the previous formulas,
but the roles of L1 and L2 are interchanged:
8. Log: a1 + a2 log(L2 + a3)
9. Cubic polynomial: a0 + a1 L2 + a2  + a3 
10. Quintic polynomial: a0 + a1 L1 + a2  + a3  + a4 
+ a5 
11. Cubic & curvature: a0 + a1 L2 + a2  + a3  + b C1
12. Quintic & curvature: a0 + a1 L2 + a2  + a3  + a4 
+ a5  + b C2
13. Quintic & GC ratio: a0 + a1 L2 + a2  + a3  + a4 
+ a5  + b GC2
14. Quintic & L1& GC ratio: a0 + a1 L2 + a2  + a3  + a4
 + a5  + b0 Log(L1) + b1 GC1
where L2, C2 and GC2 are the length, curvature and GC
ratio of the second sequence in the pair and L1 is the
length of the first sequence.
Formula coefficients were derived by regression analysis
using the Matlab robustfit procedure applied to labora-
tory RLGS spots with known sequences. Matlab robustfit
is a robust version of least squares. To avoid numerical
instability, coefficients for the quintic polynomials were
derived using Chebyshev polynomials The two sequences
determining the horizontal and vertical migration of a
laboratory spot are the two sequences associated with its
matching virtual spot. Confirmed matches produced
using vRLGS produced new spots with known sequences
that were then used to improve the prediction formula.
Thus, vRLGS was used to improve its own accuracy.
Image generation
A 300-dpi virtual RLGS image is generated from the spot
locations produced by fff2cnm.pl. Each spot is modeled
as a Gaussian distribution, exp(-(dx)2/400-(dy)2/225),
where dx and dy are the horizontal and vertical distance
from the spot location. RLGS spots have greater width
than height, and the parameters in the Gaussian distribu-
tion reflect this difference. Ribosomal DNA generates
multiple fragments with the same DNA sequence. These
fragments migrate to the same location on the gel, creat-
ing spots which are significantly larger and darker than
others. Virtual spots from ribosomal DNA are modeled as
the Gaussian distribution, exp(-(dx)2/4500-(dy)2/2500).
If two or more spots overlap, then their combined inten-
sity at a pixel is computed as 1 - (1-I1) × (1-I2) × (1-I3) × ...
where I1, I2, I3, ... is the intensity contribution from each
of the spots at the given pixel. Intensities are measured
from 0 to 1 with 0 as white and 1 as black.
Conime
Conime is a software program developed at The Ohio
State University for the comparison and analysis of RLGS
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images, identify and match image spots and measure dif-
ferences between spots. We used conime to compare lab-
oratory and virtual RLGS gels.
RLGS spot sequence confirmation
Spots identified through use of any of the three previously
published arrayed boundary librarys (human NotI-
EcoRV-HinfI [11], and AscI-EcoRV-HinfI [12] and mouse
NotI-EcoRV-HinfI [13]) were confirmed for accuracy by
the clone mixing gels approach previously described. Can-
didate sequences for spots as determined by vRLGS were
confirmed using three different methods:
A) Candidate sequences were confirmed by designing
PCR primers with the NotI-HinfI fragment of the RLGS
spot. The spot of interest and a nearby negative control
spot was eluted from the acrylamide gel as described [17]
and these eluted spot DNAs were used as template for
PCR. A candidate was deemed correct if a strong PCR
product was obtained when DNA eluted from the spot of
interest was used and either no band or a very weak band
was detected when DNA eluted from the negative control
spot was used as template. In cases where the spot of inter-
est produced a strong band and the negative control spot
produced a moderate intensity or greater band, such a
candidate was deemed to be ambiguous and is not
reported as the correct identify of the spot of interest. In
cases where the spot of interest did not amplify, the can-
didate was deemed as incorrect.
B) Using the BLAT search tool we identified a BAC clone
containing the full sequence of the candidate for the spot
of interest. The BAC clone was then used in a typical RLGS
mixing gel as previously described [3]. The candidate was
deemed as correct if the spot of interest was enhanced in
the BAC mixing gel.
C) We designed PCR primers outside the positions of the
NotI site and EcoRV site so that the amplified product
would contain the entirety of the 1st dimension NotI-
EcoRV fragment. Normal PBL genomic DNA (Promega)
was used as template for PCR and the entire PCR product
was cloned using the TOPO cloning kit (Invitrogen). The
clone was then used in typical RLGS mixing gels as previ-
ously described [11] and the candidate was deemed cor-
rect if the spot of interest was enhanced on the PCR clone
mixing gel.
Genome database
We used UCSC Genome Bioinformatics site [33] as our
source for the human and mouse fasta files containing
DNA sequences. The human sequence is from the March
2006 release (hg18). The mouse sequence is from the Feb-
ruary 2006 release (mm8) of the C57BL/6J mouse strain.
RLGS gels
We tested vRLGS on three different laboratory gels: a
human NotI-EcoRV-HinfI gel, a human AscI-EcoRV-HinfI
gel and a mouse NotI-EcoRV-HinfI gel that serve as our
"Master Profiles" as previously described [12,13,26]. For
each of the three gels, we derived a separate set of formula
coefficients predicting spot locations. Formulas for the
human NotI-EcoRV-HinfI gel were derived from a set of
683 identified spots on that gel. Formulas for the human
AscI-EcoRV-HinfI gel were derived from a set of 133 iden-
tified spots on the AscI-EcoRV-HinfI gel. Formulas for the
mouse NotI-EcoRV-HinfI gel were derived from a set of
476 spots on the mouse gel.
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